Table 5

Rationale for initial combination therapy in T2D

Early robust lowering of HbA1c
Avoidance of clinical inertia associated with a stepwise approach to therapy
Potential for early combination therapy to improve β-cell function
Initiation of therapeutic intervention with complementary mechanism of action
Potential to use less than maximal doses of individual agents to minimize side effects
Avoiding long-term consequences of metabolic memory